OHSU

Leukemia & Lymphoma Society

The mission of The Leukemia and Lymphoma Society is to cure leukemia, lymphomas, Hodgkin’s disease and myeloma and to improve the quality of life for patients and their families. Since its founding in 1949, the Society has invested more than $550 million in leukemia, lymphoma and myeloma research, $64.7 million in 2008 alone. Society-funded research has led to key advances in understanding blood cancers and the development of lifesaving drugs to fight them.

The Society’s research grants program currently supports more than 400 grants in over 14 countries. This includes $1.5 million to programs in Oregon and Southwest Washington.  The Society provides ongoing support for chronic myeloid leukemia research to Dr. Brian Druker, director of the OHSU Knight Cancer Institute, who developed the medication Gleevec. His laboratory is continuing to research new treatments for chronic myeloid leukemia.

The Society provides many services to patients with blood cancers. These include family support groups, an educational Web site, free seminars and conferences, patient financial aid and co-pay assistance for medications.  In 2008, patients in Oregon received over $129,000 for medicine and travel expenses including food, gas and lodging. The Society also helps OHSU patients meet others with blood cancer who have completed treatment and can provide emotional support.